Nuventra Pharma Sciences is pleased to announce the addition of Suliman Al-Fayoumi, PhD, MBA, to its growing team of experienced consultants. Dr. Al-Fayoumi has more than 20 years of experience in regulatory science and the pharmaceutical industry including experience in clinical pharmacology, biopharmaceutics, pharmacology, toxicology and translational sciences.
Dr. Al-Fayoumi spent eight years as a Senior Clinical Pharmacology and Biopharmaceutics Reviewer at FDA and over 12 years working for several large and small pharma/biotech companies. Dr. Al-Fayoumi has extensive experience in designing, executing, and overseeing ADME/DMPK, nonclinical pharmacology and toxicology studies, in addition to clinical pharmacology PK/PD study protocols, reports, and programs. He has received several awards recognizing his leadership abilities and outstanding work in regulatory science and contributions to drug development programs. Dr. Al-Fayoumi supported several regulatory submissions as a clinical pharmacologist and external consultant and has extensive experience interacting with key regulatory health authorities including US FDA, EMA & PMDA.
“We are excited to welcome Dr. Al-Fayoumi to the Nuventra team,” said Geoffrey Banks, Ph.D., Nuventra’s CEO, adding further, “His experience at the FDA provides our clients with the type of experience and added value they are looking for when navigating the regulatory landscape.”